We are currently in our Series A round of funding. Click here to view our investor materials.
- ENB Therapeutics Announces Clinical Trial Collaboration with Merck to Evaluate ENB-003 in combination with KEYTRUDA® (pembrolizumab) for Advanced Solid Tumors
- ENB Therapeutics Closes Series A Round of Funding
- ENB to present at 2016 Pitch Fest organized by New York Bio
- ENB CSO and Co-founder Dr. Sumayah Jamal wins Best-in-show at 1st Pitch Life Science NYC
- ENB Therapeutics accepted for presentation at the 2016 HemOnc Today Melanoma Conference in NYC